fashion -WSS

fashion

author：comprehensive 2025-10-02 21:00:37 - browse：739

A vial of Tofersen injection on the left of its box — The ALS drug tofersen is marketed as Qalsody in the U.S. Biogen

LONDON — Neurologists and patient advocates are up in arms over a policy decision by a U.K. health agency that they say will imperil access to an ALS treatment that’s available in the U.S. and on its way to approval in the European Union.

The medicine in question, Biogen’s tofersen, is designed to treat a rare genetic form of the neurodegenerative disease, accounting for some 2% of all ALS cases. And the issue is how the U.K.’s cost-effectiveness agency has said it would assess the costs and benefits of the therapy.

The agency, the National Institute for Health and Care Excellence, or NICE, has a special pathway for drugs for very rare diseases, which advocates and doctors argue is the route through which tofersen should be reviewed. But NICE has indicated it would review the drug through its standard process, saying it’s because ALS as a whole does not count as a “very rare” disease. That sets a higher bar to clear.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： What Mike Pence has said that could be used in a Donald Trump trial

WSS

Carbon Health diabetes program, a test of data

What the cancer research community can learn from the Covid response

A cyberattack has disrupted hospitals and health care in several states

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

White House drug shortage group privately met with industry

Study suggests Covid rebound is far more common with Paxlovid than without

focus

fashion

explore

Novavax promises a turnaround & Lilly roils the obesity market

Verily hires former Apple Health leader as chief scientific officer

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Bright Health sells Medicare Advantage business to Molina

Study suggests Covid rebound is far more common with Paxlovid than without

Apple is now the first public company to be valued at $3 trillion

Stem cell clinics for heart failure: buyer be wary

How to save PrEP access — and even expand it

Microsoft strikes partnership with Duke Health to advance health AI

knowledge

Verily hires former Apple Health leader as chief scientific officer

Gilgo Beach: Police identify another victim in serial killing investigation

Nearly two

Nearly two

Medicare’s new pay boost for primary care is angering specialists

Medicare’s new pay boost for primary care is angering specialists

entertainment

focus

focus

focus